Iterum Therapeutics PLC (ITRM) - Total Liabilities
Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) has total liabilities worth $39.88 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ITRM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Iterum Therapeutics PLC - Total Liabilities Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Iterum Therapeutics PLC assets under control.
Iterum Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Iterum Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fidelity Japanese Values PLC ORD
LSE:FJV
|
UK | GBX2.64 Million |
|
Bluelinea SA
PA:ALBLU
|
France | €8.79 Million |
|
Capricorn Energy PLC
LSE:CNE
|
UK | GBX139.75 Million |
|
Magnetic North Acquisition Corp
V:MNC
|
Canada | CA$4.68 Million |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
UK | GBX1.66 Million |
|
Olympio Metals Ltd
AU:OLY
|
Australia | AU$810.12K |
|
EQTEC plc
LSE:EQT
|
UK | £9.22 Million |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
Australia | AU$100.91K |
Liability Composition Analysis (2016–2024)
This chart breaks down Iterum Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ITRM equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Iterum Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual total liabilities of Iterum Therapeutics PLC from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $48.68 Million | +49.03% |
| 2023-12-31 | $32.66 Million | -15.89% |
| 2022-12-31 | $38.83 Million | -5.91% |
| 2021-12-31 | $41.27 Million | -50.48% |
| 2020-12-31 | $83.35 Million | +60.32% |
| 2019-12-31 | $51.99 Million | +98.06% |
| 2018-12-31 | $26.25 Million | +261.41% |
| 2017-12-31 | $7.26 Million | +70.93% |
| 2016-12-31 | $4.25 Million | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more